The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial.
 
Niranjan Sathyanarayana Rao
Employment - Asana Biosciences
Stock and Other Ownership Interests - Asana Biosciences
 
Anthony W. Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics; ArQule; Asana Biosciences; Astex Pharmaceuticals; Bayer Schering Pharma; Bind Therapeutics; Blend Therapeutics; Celator; Dicerna; Endocyte; Genmab; Heron; Janssen; Johnson & Johnson; Johnson & Johnson; Mersana; Merus; Nanobiotix; Pharmacyclics; Pierre Fabre; Proximagen; Symphony Evolution; Upsher-Smith; Valent Technologies
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Pfizer (Inst); TaiRx, Inc. (Inst)
 
Kyriakos P. Papadopoulos
Research Funding - Abbvie (Inst); ARMO BioSciences (Inst); ArQule (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Novartis (Inst); Onyx (Inst); Regeneron (Inst); Sanofi (Inst)
 
Drew W. Rasco
Research Funding - Aeglea Biotherapeutics; Asana Biosciences; Bayer; Celgene; Eisai; Five Prime Therapeutics; Pharmacyclics; Rexahn Pharmaceuticals; Santa Maria Biotherapeutics; Takeda
Travel, Accommodations, Expenses - Takeda
 
Naomi B. Haas
Stock and Other Ownership Interests - TetraLogic Pharmaceuticals (I)
Expert Testimony - Lilly (I)
 
Allan J. Pantuck
No Relationships to Disclose
 
Louis J. Denis
Employment - Asana Biosciences
Leadership - Asana Biosciences
Stock and Other Ownership Interests - Asana Biosciences
 
Robert Dreicer
Honoraria - Astellas Pharma
Consulting or Advisory Role - Asana Biosciences; Astellas Pharma; BIND Biosciences; Dendreon; Medivation; Merck; Millennium; Roche
Research Funding - Progenics (Inst)